Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH 72 Debt-to-EBITDA is 2.92 as of Mar. 2026, which is 28% below its 10-year median of 4.07. GuruFocus rates XSWX:ZBH with a GF Score™ of 72/100 and a GF Value™ of CHF103.31. The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks worse than 72.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Zimmer Biomet Holdings's Debt-to-EBITDA or its related term are showing as below:
XSWX:ZBH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.6 Med: 4.07 Max: 8.44
Current: 3.24
During the past 13 years, the highest Debt-to-EBITDA Ratio of Zimmer Biomet Holdings was 8.44. The lowest was 2.60. And the median was 4.07.
XSWX:ZBH's Debt-to-EBITDA is ranked worse than 72.16% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs XSWX:ZBH: 3.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Zimmer Biomet Holdings Debt-to-EBITDA Related Terms
Zimmer Biomet Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZBH vs STE, PEN, GMED: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Zimmer Biomet Holdings (XSWX:ZBH) has a Debt-to-EBITDA of 2.92 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zimmer Biomet Holdings. This is 28% below median its historical median of 4.07. Over the past decade, Zimmer Biomet Holdings' Debt-to-EBITDA has ranged from 2.60 to 8.44. According to the industry distribution chart, Zimmer Biomet Holdings ranks #337 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 72.2%.
Is Zimmer Biomet Holdings' Debt-to-EBITDA too high?
Zimmer Biomet Holdings' current Debt-to-EBITDA of 2.92 is 28% below median its 10-year median of 4.07. Over the past 10 years, this metric has ranged from a low of 2.60 to a high of 8.44. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Zimmer Biomet Holdings' value of 2.92 is 86% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #337 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Debt-to-EBITDA compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #337 out of 467 companies for Debt-to-EBITDA. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Zimmer Biomet Holdings' value of 2.92 is 86% above this benchmark. Historically, Zimmer Biomet Holdings' own Debt-to-EBITDA has ranged from 2.60 to 8.44 over the past decade. While the company's 10-year median is 4.07 vs. the industry median of 1.57, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Debt-to-EBITDA of 2.92 is 86% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zimmer Biomet Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Debt-to-EBITDA is 2.92, which is 28% below median its own 10-year median of 4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current Debt-to-EBITDA of 2.92. The stock's GF Value™ is CHF103.31, compared to a current price of CHF74.50 — trading 27.9% below its estimated fair value. The current Debt-to-EBITDA is 2.92, which is 28% below median its 10-year median of 4.07 and 86% above the Medical Devices & Instruments industry median of 1.57. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Debt-to-EBITDA is 2.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF74.50 is trading 27.9% below its estimated GF Value™ of CHF103.31.
Key valuation signals for XSWX:ZBH:
Debt-to-EBITDA: 2.92 (28% below median its 10-year median of 4.07)
GF Value™: CHF103.31 vs. price of CHF74.50 (27.9% below fair value)
Industry Position: 86% above the Medical Devices & Instruments median (#337 of 467)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score
Get the complete analysis for XSWX:ZBH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
